ISO 10993 Is Not a Clinical Evaluation Shortcut
I see it regularly in dossiers. A manufacturer submits a full set of ISO 10993 biocompatibility reports. Clean results. Well documented. Then they assume the biological safety chapter of their clinical evaluation is done. The Notified Body comes back with a major finding. Why? Because biocompatibility testing and clinical evaluation serve different purposes, and one does not replace the other.
In This Article
This is not a theoretical issue. It comes up in audits, in CER reviews, and in pre-submission meetings. The confusion is understandable. Both ISO 10993 and the clinical evaluation process address safety. Both are mandatory under MDR. But they operate at different levels of evidence, and they answer different questions.
The problem is that many teams treat biocompatibility as a checkbox. Once the reports are filed, they move on. The clinical evaluation then echoes the ISO 10993 conclusions without interpreting them in the context of actual use. That gap is what reviewers catch.
What ISO 10993 Actually Does
ISO 10993 is a standard for biological evaluation of medical devices. It provides a framework for testing materials and finished devices to assess their interaction with living tissue. The tests cover cytotoxicity, sensitization, irritation, systemic toxicity, and depending on device contact type and duration, other endpoints like genotoxicity, implantation response, hemocompatibility, and carcinogenicity.
The standard helps manufacturers demonstrate that materials are not immediately harmful in controlled laboratory conditions. It is a necessary step. It provides objective, reproducible data. But it operates in a constrained environment. Animal models. In vitro assays. Defined exposure scenarios. Short observation periods in many cases.
ISO 10993 does not tell you what happens when the device is used for years in a diabetic patient with impaired healing. It does not predict how a coating degrades in an inflammatory environment. It does not account for interactions with other implanted devices or concurrent medications.
ISO 10993 provides preclinical biological safety data. Clinical evaluation integrates that data with real-world evidence to assess safety and performance in the target population under actual conditions of use.
Why This Creates a Gap
The issue becomes visible when you compare what the two processes deliver. ISO 10993 testing happens early. It often uses materials or prototypes. The testing conditions are standardized and artificial. The results tell you whether the device passes a safety threshold in a laboratory.
Clinical evaluation happens later. It considers the final device, the intended users, the clinical environment, the duration of exposure, the patient population, comorbidities, and everything else that affects real-world outcomes. It must assess whether the device remains safe and performs as intended when all those variables are in play.
Here is where teams go wrong. They write a section in the CER titled
Frequently Asked Questions
What is a Clinical Evaluation Report (CER)?
A CER is a mandatory document under MDR 2017/745 that demonstrates the safety and performance of a medical device through systematic analysis of clinical data. It must be updated throughout the device lifecycle based on PMCF findings.
How often should the CER be updated?
The CER should be updated whenever significant new clinical data becomes available, after PMCF activities, when there are changes to the device or intended purpose, and at minimum during annual reviews as part of post-market surveillance.
What causes CER rejection by Notified Bodies?
Common reasons include inadequate equivalence demonstration, insufficient clinical data for claims, poorly structured SOTA analysis, missing gap analysis, and lack of clear benefit-risk determination. Structure and logical flow are as important as the data itself.
Which MDCG guidance documents are most relevant for clinical evaluation?
Key documents include MDCG 2020-5 (Equivalence), MDCG 2020-6 (Sufficient Clinical Evidence), MDCG 2020-13 (CEAR Template), MDCG 2020-7 (PMCF Plan), and MDCG 2020-8 (PMCF Evaluation Report). ISO 10993, MDCG 2020-6
Need Expert Help with Your Clinical Evaluation?
Get personalized guidance on MDR compliance, CER writing, and Notified Body preparation.
✌
Peace, Hatem
Your Clinical Evaluation Partner
Follow me for more insights and practical advice.
Deepen Your Knowledge
Read Complete Guide to Clinical Evaluation under EU MDR for a comprehensive overview of clinical evaluation under EU MDR 2017/745.
